The Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s already been a busy month for the biotech IPO queue.
An article from
Dive Brief
//
IPO window
The Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s already been a busy month for the biotech IPO queue.
Documento da empresa sediada em Thousand Oaks, Califórnia, não indica quantas ações ela planeja vender nem o montante que…
After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech…
From the co-founders of Turning Point, BlossomHill Therapeutics filed its IPO paperwork as it tests a macrocyclic small molecule…
It’s the latest in a string of deals for Lilly, which has sunk more than $18 billion into acquisitions over the past few years.
Latigo Biotherapeutics Appoints Todd Smith to its Board of Directors
VANCOUVER, BC / ACCESS Newswire / June 1, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage…
